Your studies
Clinical Trial Management System · All India Institute of Ayurveda, New Delhi — National Pharmacovigilance Coordination Centre for ASU&H drugs
Signed in as Principal Investigator
Active studies
10 in scope for this role
Total enrolled vs target
43% of target across 10 studies
Open adverse events
33 events recorded in total
Open data queries
15 open beyond 21 days
Protocol deviations
3 major or critical
Overdue monitoring visits
TAM, YAK
Study portfolio
10 of 10 studies visible to Principal Investigator · Own studies · full participant detail
Alerts
3 critical · 4 at risk · 1 watch
Last monitored 2026-05-28. Visit was scheduled for 2026-08-19.
rule: Monitoring.nextVisit < today
Last monitored 2026-06-11. Visit was scheduled for 2026-09-02.
rule: Monitoring.nextVisit < today
Hepatic enzyme increased · AIIA-SAN-DEL-007 · to Sponsor, Ethics Committee and CDSCO
rule: SAE.initialReport ≤ 24h (NDCT Rules 2019)
EC approved 2026-08-27. NDCT requires CLA notification within 15 days.
rule: CLA.notification ≤ 15d of EC approval
Femur fracture · AIIA-AMV-JAM-003 · initial report already transmitted
rule: SAE.detailedReport ≤ 14d (NDCT Rules 2019)
9 of 30 enrolled (30%) 5 months after registration.
rule: Enrolment.actual/target < 40% after 3 months
7 of 22 enrolled (32%) 4 months after registration.
rule: Enrolment.actual/target < 40% after 3 months
6 of 16 enrolled (38%) 4 months after registration.
rule: Enrolment.actual/target < 40% after 3 months
Enrolment over time
Cumulative accrual against the planned curve, summed across studies in scope
Studies by lifecycle stage
Where each study currently sits in the protocol-to-close-out pipeline
Studies by therapeutic area
Portfolio spread across clinical domains